

NOVARTIS AG  
Form 6-K  
May 22, 2007

## SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

### FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 or 15d-16 OF  
THE SECURITIES EXCHANGE ACT OF 1934

Report on Form 6-K dated May 21, 2007

(Commission File No. 1-15024)

**Novartis AG**

(Name of Registrant)

Lichtstrasse 35  
4056 Basel  
Switzerland

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F:  Form 40-F:

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes:  No:

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes:  No:

Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes:  No:

**Novartis International AG**  
Novartis Global Communications  
CH-4002 Basel  
Switzerland  
<http://www.novartis.com>

**- Investor Relations Release -**

**Focetria®, the Novartis pandemic influenza vaccine, receives European Union approval**

- *Focetria to allow for more rapid response in the event of an influenza pandemic, to be adapted with identified viral strain after WHO pandemic declaration*
- *Focetria includes MF59 adjuvant boosts the body's immune system and enhances protection with a lower dose of a viral antigen than other vaccines*

**Basel, May 8, 2007** Focetria®, a new human vaccine designed for use following the declaration of an influenza pandemic, has received European Union approval in all 27 member states as well as Iceland and Norway.

Focetria will be manufactured to contain the influenza strain declared at the time of a pandemic by the World Health Organization (WHO). It will also include the proprietary adjuvant MF59, which was developed by Novartis and could extend the vaccine supply by allowing for smaller amounts of viral antigens to be used in each dose compared to vaccines without this additive.

Novartis is pleased with this positive decision by the European Commission for Focetria, said Dr. Jörg Reinhardt, CEO of Novartis Vaccines and Diagnostics, a division of Novartis. The approval of this vaccine, which incorporates our proprietary MF59 adjuvant, marks an important milestone in preparations to combat a potential pandemic threat.

Once the WHO declares a pandemic, Novartis will submit a revised application to the European Medicines Agency (EMA) to incorporate the identified viral strain. The Focetria mock-up file submitted for EU approval in early 2006 was based on clinical studies involving the MF59 adjuvant and different influenza strains with pandemic potential, including H5N1 and H9N2.

Separately, Novartis has submitted for European Union approval a pre-pandemic H5N1 influenza vaccine incorporating the MF59 adjuvant and based on the same technology as Focetria. This vaccine is intended for use prior to the declaration of a pandemic to help bolster the immune system of those receiving it to better defend against infections from a H5N1 virus.

**Novartis commitment to pandemic preparedness**

Novartis is working closely with government and regulatory officials worldwide to support pandemic preparedness efforts. Novartis has engaged in discussions with several governments concerning pandemic influenza vaccine supply and has received contracts to provide H5N1 vaccines for stockpiling.

Novartis is committed to supporting leadership initiatives by the WHO to ensure public safety in case of a pandemic, including the development of a global pandemic vaccine stockpile for developing countries. Novartis is also supportive of the WHO's leadership role in global pandemic planning. The WHO is a key global hub for pandemic preparedness, ensuring cohesion and coordination amongst all players involved, including the industry, governments of both developed or developing countries and their populations.

In January 2007, the US Department of Health and Human Services (HHS) awarded Novartis a USD 55 million contract to further develop the MF59 adjuvant technology for use in potentially extending vaccine supplies in case of a pandemic outbreak. An adjuvant is a substance added to a vaccine to enhance the body's immune response to the vaccine's active constituent, called the antigen.

Novartis has also developed a new influenza vaccine manufacturing process that utilizes a proprietary cell line, rather than chicken eggs, for antigen production. The Novartis proprietary cell culture technology may reduce production time to meet demands of influenza outbreaks and may also help to develop antigens for a wider range of viral strains that are difficult to grow in eggs. These are two important production advantages in the event of an influenza pandemic.

**About H5N1 avian influenza**

Global health authorities have identified H5N1 avian influenza as an aggressive viral strain with pandemic potential. While researchers have not quantified the likelihood of an outbreak, to date H5N1 has caused serious illness in Southeast Asia in more than 250 people. The mortality rate of patients investigated has been over 50%(1).

An influenza pandemic outbreak is expected to spread quickly globally, so the licensing and production of sufficient quantities of pandemic vaccines is considered an enormous challenge. The WHO has recommended early development of vaccines and their use to reduce disease severity and mortality in the event of an outbreak. The WHO has further stressed the need to work collaboratively with researchers and vaccine manufacturers to ensure that the largest possible amount of vaccines and antiviral drugs are available at the outbreak of a pandemic(2).

---

### References

(1) WHO Cumulative Number of Confirmed Human Cases of Avian Influenza, WHO Web site

[http://www.who.int/csr/disease/avian\\_influenza/country/cases\\_table\\_2006\\_10\\_31/en/index.html](http://www.who.int/csr/disease/avian_influenza/country/cases_table_2006_10_31/en/index.html), accessed February 6, 2007

(2) WHO Strategic Action Plan for Pandemic Influenza 2006-2007, WHO website

[http://www.who.int/csr/resources/publications/influenza/WHO\\_CDS\\_EPR\\_GIP\\_2006\\_2c.pdf](http://www.who.int/csr/resources/publications/influenza/WHO_CDS_EPR_GIP_2006_2c.pdf), accessed February 6, 2007

### Disclaimer

This release contains certain forward-looking statements, relating to the Novartis Group's business, which can be identified by the use of forward-looking terminology such as may, could, potential, committed, will, can, or similar expressions, or by express or implied discussion regarding potential marketing approvals, future sales or effectiveness of Focetria or other vaccines, or regarding the potential successfulness of new and advanced manufacturing technology. Such forward-looking statements reflect current views with respect to future events and are subject to certain risks, uncertainties and assumptions that may cause actual results with Focetria to be materially different from any future sales, performance or achievements expressed or implied by such statements. There can be no guarantee that Focetria or other vaccines will be approved for any indications in any market, that Focetria or any vaccines will reach any particular

sales levels, or that a market for Focetria will develop. In particular, management's expectations regarding Focetria and other vaccines could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; unexpected clinical trial results, including additional analysis of existing clinical data and new clinical data; competition in general; the ability of Novartis to obtain or maintain patent or other proprietary intellectual property protection; increased government, industry, and general public pricing pressures; and other risks and factors referred to in the Novartis AG's current Form 20-F on file with the U.S. Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

**About Novartis**

## Edgar Filing: NOVARTIS AG - Form 6-K

Novartis Vaccines and Diagnostics is a division of Novartis focused on the development of preventive treatments and tools. Novartis Vaccines is the world's fifth-largest manufacturer and second-largest supplier of influenza vaccines in the US. The division's products also include meningococcal, pediatric and travel vaccines. Chiron, the blood testing and molecular diagnostics business, is dedicated to preventing the spread of infectious diseases through the development of novel blood-screening tools that protect the world's blood supply.

**Novartis AG (NYSE: NVS) is a world leader in offering medicines to protect health, cure disease and improve well-being. Our goal is to discover, develop and successfully market innovative products to treat patients, ease suffering and enhance the quality of life. We are strengthening our medicine-based portfolio, which is focused on strategic growth platforms in innovation-driven pharmaceuticals, high-quality and low-cost generics, human vaccines and leading self-medication OTC brands. Novartis is the only company with leadership positions in these areas. In 2006, the Group's businesses achieved net sales of USD 37.0 billion and net income of USD 7.2 billion. Approximately USD 5.4 billion was invested in R&D. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 100,000 associates and operate in over 140 countries around the world.**

For more information, please visit <http://www.novartisvaccines.com>.

# # #





**Novartis Media Relations**

**John Gilardi**

**Novartis Global Media Relations**

**+41 61 324 3018 (direct)**

**+41 79 596 1408 (mobile)**

**john.gilardi@novartis.com**

**Eric Althoff**

**Novartis Vaccines and Diagnostics Communications**

+1-510-923-6500

+1-510-387-7604(US mobile)

**eric.althoff@novartis.com**



## Edgar Filing: NOVARTIS AG - Form 6-K

e-mail: [media.relations@novartis.com](mailto:media.relations@novartis.com) or [nvd.communications@novartis.com](mailto:nvd.communications@novartis.com)

### Media materials

For images and video related to the Novartis Vaccines influenza products, please visit [www.thenewsmarket.com/novartisvaccines](http://www.thenewsmarket.com/novartisvaccines). Journalists may register and download print-quality images and broadcast-standard video from this site at no charge.

### Novartis Investor Relations

#### International

<b>Ruth Metzler-Arnold</b>	+41 61 324 7944
Katharina Ambühl	+41 61 324 5316
Nafida Bendali	+41 61 324 3514
Jason Hannon	+41 61 324 2152
Richard Jarvis	+41 61 324 4353

#### North America

<b>Ronen Tamir</b>	+1 212 830 2433
Arun Nadiga	+1 212 830 2444
Jill Pozarek	+1 212 830 2445
Edwin Valeriano	+1 212 830 2456

e-mail: [investor.relations@novartis.com](mailto:investor.relations@novartis.com)

5

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Novartis AG**

Date: May 21, 2007

By: /s/ Malcolm B. Cheetham

Name: Malcolm B. Cheetham  
Title: Head Group Financial  
Reporting and Accounting

6

---